A retrospective study on cancer patients under PD1 Ab therapy (nivolumab, pembrolizumab) associated elevated blood levels of thyroid-stimulating hormone (TSH) and thyroglobulin Ab with early onset of IRAE and prolonged survival, proposing IRAE as predictive markers for clinical outcome [80]. The gene discussed is PDCD1; the disease is cancer.